Desmoid Tumor Clinical Trial
Official title:
PHASE II STUDY OF THE SAFETY AND EFFICACY OF TOREMIFENE IN THE THERAPY OF DESMOID TUMORS
RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using
toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.
PURPOSE: Phase II trial to study the effectiveness of toremifene in treating patients with
desmoid tumors.
OBJECTIVES: I. Determine the efficacy of toremifene in terms of tumor response rate and
symptom relief in patients with desmoid tumors. II. Determine the safety of this regimen in
these patients. III. Determine the quality of life of patients treated with this regimen.
OUTLINE: Patients are stratified by gender. Patients receive oral toremifene daily until
complete or maximal response in the absence of disease progression or unacceptable toxicity.
Patients achieving maximal response undergo complete resection of all lesions, if feasible.
Nonsurgical candidates with severe or life-threatening disease not achieving partial or
complete response or symptom relief at 12 months may continue on toremifene at the
discretion of the study chairperson. Patients with stable disease who do not undergo surgery
may continue on toremifene for a maximum of 12 months at the discretion of the treating
physician. Patients who continue to experience symptom relief at 12 months may continue on
toremifene at the discretion of the study chairperson. Quality of life is assessed at
baseline and at 2 and 6 months. Patients are followed every 8 weeks for 4 years and then
annually thereafter.
PROJECTED ACCRUAL: A total of 24-72 (12-36 per stratum) will be accrued for this study.
;
Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561036 -
A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor
|
Phase 3 | |
Completed |
NCT00287846 -
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06258421 -
Burden of Disease and Living Situation in Desmoid Patients
|
||
Completed |
NCT00030680 -
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
|
Phase 2 | |
Recruiting |
NCT06081400 -
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
|
N/A | |
Active, not recruiting |
NCT04871282 -
A Study of AL102 in Patients With Progressing Desmoid Tumors
|
Phase 2/Phase 3 | |
Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
Completed |
NCT01137916 -
Study to Evaluate Imatinib in Desmoid Tumors
|
Phase 2 | |
Completed |
NCT03459469 -
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
|
Phase 1 | |
Completed |
NCT06195085 -
CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
|
||
Completed |
NCT01286662 -
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
|
N/A | |
Completed |
NCT01265030 -
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
|
Phase 1/Phase 2 | |
Completed |
NCT00068419 -
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
|
Phase 2 | |
Completed |
NCT04289077 -
Quality of Life of Patients With Desmoid-type Fibromatosis
|
||
Completed |
NCT03190174 -
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00003019 -
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
|
Phase 2 | |
Recruiting |
NCT05949099 -
Study of Cryoablation and Nirogacestat for Desmoid Tumor
|
Phase 2 | |
Active, not recruiting |
NCT02076906 -
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
|
Phase 1 | |
Completed |
NCT00474994 -
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT03785964 -
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
|
Phase 3 |